Federico Vázquez
Research Subjects
Federico Vázquez has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Santos
Endocrinology/Medicine Department, Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), IIB-Sant Pau, ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
1 shared publication - Angela Casas
Department of Nephrology, University Hospital Germans Trias i Pujol (HGTiP), 08916 Badalona, Spain
1 shared publication - Anna Vila
Department of Nephrology, University Hospital Germans Trias i Pujol (HGTiP), 08916 Badalona, Spain
1 shared publication - Berta Soldevila
Endocrinology and Nutrition Service, Hospital Germans Trias i Pujol , 08916 Badalona
1 shared publication - Didac Mauricio
CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Barcelona, Spain
1 shared publication Diego Asensio-Wandosell
Endocrinology and Nutrition Service, Germans Trias i Pujol Hospital and Research Institute 5
1 shared publication
Latest Publications
- Open Access
- 11 April 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (5)
Quality of life and psychological status in people with acromegaly in relation to disease-related facial changes
The diagnosis of acromegaly is often delayed, leading to facial disfigurements that persist despite endocrine cure. We aimed to study the relationship between facial modifications, quality of life (QoL) and psychological status in patients with acromegaly. Methods: Sixty-five patients in remission or with hormonal disease control participated (29 women and 36 men; mean age 57.4 ± 13.5 years). The following variables were assessed: i) sex; ii) QoL by AcroQoL; iii) anxiety level with the STAI questionnaire; iv) self-esteem by the Rosenberg scale; and v) facial acromegaly phenotypical changes evaluated from face photographs by eight experienced endocrinologists using a Likert scale. Results: The global AcroQoL score for the whole cohort showed mid-range values, with higher median values for men (72.3 vs 56.6, P = 0.022) mostly dependent on the physical domain, which was higher for men (59.0 vs 34.9, P = 0.006), rather than the psychological domain (65.7 vs 54.5, P = 0.069). Anxiety scores were also higher for women (7.3 vs 5.9, P = 0.009). Self-esteem state was high (2.7 ± 0.6 for a maximal value of 3) for the whole cohort without sex differences. A higher difference in the global phenotypic facial acromegaly features score from baseline and post-diagnosis was associated with a lower value on QoL mostly in women (−14.38 95% CI −5.25 to −23.52; P-value = 0.005), with less effect in men (−6.31 95% CI 0.61 to −13.22; P-value = 0.070). Conclusion: In controlled acromegaly, QoL is relatively preserved in both genders, although men have higher general and physical domain scores and lower anxiety status. Facial changes intensity negatively impacted QoL mostly in women.
- 11 April 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (5)
Open AccessQuality of life and psychological status in people with acromegaly in relation to disease-related facial changes
The diagnosis of acromegaly is often delayed, leading to facial disfigurements that persist despite endocrine cure. We aimed to study the relationship between facial modifications, quality of life (QoL) and psychological status in patients with acromegaly. Methods: Sixty-five patients in remission or with hormonal disease control participated (29 women and 36 men; mean age 57.4 ± 13.5 years). The following variables were assessed: i) sex; ii) QoL by AcroQoL; iii) anxiety level with the STAI questionnaire; iv) self-esteem by the Rosenberg scale; and v) facial acromegaly phenotypical changes evaluated from face photographs by eight experienced endocrinologists using a Likert scale. Results: The global AcroQoL score for the whole cohort showed mid-range values, with higher median values for men (72.3 vs 56.6, P = 0.022) mostly dependent on the physical domain, which was higher for men (59.0 vs 34.9, P = 0.006), rather than the psychological domain (65.7 vs 54.5, P = 0.069). Anxiety scores were also higher for women (7.3 vs 5.9, P = 0.009). Self-esteem state was high (2.7 ± 0.6 for a maximal value of 3) for the whole cohort without sex differences. A higher difference in the global phenotypic facial acromegaly features score from baseline and post-diagnosis was associated with a lower value on QoL mostly in women (−14.38 95% CI −5.25 to −23.52; P-value = 0.005), with less effect in men (−6.31 95% CI 0.61 to −13.22; P-value = 0.070). Conclusion: In controlled acromegaly, QoL is relatively preserved in both genders, although men have higher general and physical domain scores and lower anxiety status. Facial changes intensity negatively impacted QoL mostly in women.
- Open Access
- 7 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1048
Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment
Diabetes mellitus (DM) in kidney transplant recipients (KTR) is a risk factor for mortality, increases the risk of infections and, in the long term, can lead to graft loss due to diabetic kidney disease. A preventive approach applied to those on the waiting list could decrease the incidence of post-transplant DM (PTDM) by detecting those patients at risk, thus allowing strategies to minimize the probability of developing a New Onset Diabetes After Transplant (NODAT). On the other hand, modifications of immunosuppressive therapy may improve glucose control in patients with KTR. In recent years, two new classes of antidiabetic drugs and non-steroidal mineralocorticoid receptor antagonists have demonstrated cardiovascular and renal benefits in randomized clinical trials where the transplant population has not been represented. Because of the potential benefit expected in this population, the clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i) and finerenone is increasing in the kidney transplant setting. This review focuses on comprehensive pharmacological interventions in KTR with glucose metabolism disorders. In-depth knowledge in this area will allow prevention and identification of potential adverse effects or drug interactions in the clinical course of KTR with DM.
- 7 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1048
Open AccessDiabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment
Diabetes mellitus (DM) in kidney transplant recipients (KTR) is a risk factor for mortality, increases the risk of infections and, in the long term, can lead to graft loss due to diabetic kidney disease. A preventive approach applied to those on the waiting list could decrease the incidence of post-transplant DM (PTDM) by detecting those patients at risk, thus allowing strategies to minimize the probability of developing a New Onset Diabetes After Transplant (NODAT). On the other hand, modifications of immunosuppressive therapy may improve glucose control in patients with KTR. In recent years, two new classes of antidiabetic drugs and non-steroidal mineralocorticoid receptor antagonists have demonstrated cardiovascular and renal benefits in randomized clinical trials where the transplant population has not been represented. Because of the potential benefit expected in this population, the clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i) and finerenone is increasing in the kidney transplant setting. This review focuses on comprehensive pharmacological interventions in KTR with glucose metabolism disorders. In-depth knowledge in this area will allow prevention and identification of potential adverse effects or drug interactions in the clinical course of KTR with DM.
- Open Access
- 1 December 2017
- Published by Elsevier in Journal of Clinical and Translational Endocrinology: Case Reports
- Vol. 6, 11-13
Sustained spontaneous partial remission in a pediatric patient with type 1 diabetes
- 1 December 2017
- Published by Elsevier in Journal of Clinical and Translational Endocrinology: Case Reports
- Vol. 6, 11-13
Open AccessSustained spontaneous partial remission in a pediatric patient with type 1 diabetes
- 1 September 2016
- Published by Elsevier in Medicine - Programa de Formación Médica Continuada Acreditado
- Vol. 12 (17) , 971-981
Neuropatía diabética y pie diabético
- 1 September 2016
- Published by Elsevier in Medicine - Programa de Formación Médica Continuada Acreditado
- Vol. 12 (17) , 971-981
Neuropatía diabética y pie diabético